These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12384159)

  • 1. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen.
    Sokoll LJ; Bruzek DJ; Dua R; Dunn W; Mohr P; Wallerson G; Eisenberger M; Partin AW; Chan DW
    Urology; 2002 Oct; 60(4 Suppl 1):24-30. PubMed ID: 12384159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of three molecular forms of prostate-specific antigen ratios in patients with prostate adenocarcinoma.
    Okegawa T; Kato M; Nutahara K; Higashihara E
    Urology; 2001 May; 57(5):936-42. PubMed ID: 11337298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
    Ulmert D; Becker C; Nilsson JA; Piironen T; Björk T; Hugosson J; Berglund G; Lilja H
    Clin Chem; 2006 Feb; 52(2):235-9. PubMed ID: 16384894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
    Naya Y; Fritsche HA; Cheli CD; Stamey TA; Bartsch G; Brawer MK; Childs S; Taneja SS; Lepor H; Partin AW; Sokoll LJ; Chan DW; Babaian RJ
    Urology; 2003 Dec; 62(6):1058-62. PubMed ID: 14665355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
    Naya Y; Stamey TA; Cheli CD; Partin AW; Sokoll LJ; Chan DW; Brawer MK; Taneja SS; Lepor H; Bartsch G; Childs S; Fritsche HA; Babaian RJ
    Urology; 2002 Oct; 60(4 Suppl 1):36-41. PubMed ID: 12384161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
    Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
    BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
    Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
    BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.
    Taneja SS; Hsu EI; Cheli CD; Walden P; Bartsch G; Horninger W; Babaian RJ; Fritsche HA; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Lepor H
    Urology; 2002 Oct; 60(4 Suppl 1):10-7. PubMed ID: 12384157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of various combinations of free, complexed and total prostate-specific antigen levels as predictors of the pathologic stage of prostate cancer.
    Okegawa T; Noda H; Ohta M; Kato M; Nutahara K; Higashihara E
    Int J Urol; 2001 Aug; 8(8):438-43. PubMed ID: 11555010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.